REPL
Bearish signalScored 2026-08-14 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Replimune Group, Inc.
- Nom
- Replimune Group, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.1B
- Employés
- 465
- PDG
- Sushil Patel
- Site web
- https://www.replimune.com
- Marché
- ADAGAGENCGENCTMXIBRXIOVA
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 39 341 titres (~510 252,77 $ US)
- Insiders
- Patel Sushil
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,038,364
Avg sell (VWAP, 90d window) $13.12 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-17 | Hill Emily Luisa | Sell · S | 9,256 | $14.28 | $132,176 | Form 4 |
| 2026-08-10 | Hill Emily Luisa | Sell · S | 11,448 | $12.97 | $148,481 | Form 4 |
| 2026-08-10 | Patel Sushil | Sell · S | 39,341 | $12.97 | $510,253 | Form 4 |
| 2026-08-10 | Schwendenman Andrew | Sell · S | 7,632 | $12.97 | $98,987 | Form 4 |
| 2026-08-10 | Xynos Konstantinos | Sell · S | 11,447 | $12.97 | $148,468 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-08-14 Drivers: fundamentals. Moteurs : fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Bearish signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 4.79 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 4.794 | 7.952 | 10.724 | 17.520 | 19.463 | |
| Quick Ratio | 4.794 | 7.952 | 10.724 | 17.520 | 19.463 | |
| Solvency Ratio | -1.869 | -1.782 | -1.861 | -1.882 | -2.271 | |
| Cash Ratio | 3.590 | 1.782 | 1.841 | 4.334 | 5.104 | |
| Price To Earnings Ratio | -2.263 | -3.176 | -2.386 | -5.906 | -7.513 | |
| Price To Earnings Growth Ratio | -0.224 | 0.605 | -0.285 | -0.183 | -0.258 | |
| Forward Price To Earnings Growth Ratio | -0.224 | 0.605 | -0.285 | -0.183 | -0.258 | |
| Price To Earnings Diluted Ratio | -2.263 | -3.176 | -2.386 | -5.906 | -7.513 | |
| Price To Earnings Diluted Growth Ratio | -0.224 | 0.605 | -0.285 | -0.183 | -0.258 | |
| Price To Book Ratio | 4.273 | 1.889 | 1.374 | 1.851 | 2.156 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -2.495 | -3.948 | -2.692 | -7.889 | -10.490 | |
| Price To Operating Cash Flow Ratio | -2.532 | -4.086 | -2.775 | -8.028 | -10.788 | |
| Debt To Assets Ratio | 0.336 | 0.138 | 0.156 | 0.094 | 0.071 | |
| Debt To Equity Ratio | 0.672 | 0.183 | 0.203 | 0.109 | 0.080 | |
| Debt To Capital Ratio | 0.402 | 0.155 | 0.168 | 0.099 | 0.074 | |
| Long Term Debt To Capital Ratio | 0.334 | 0.100 | 0.107 | 0.049 | 0.000 | |
| Financial Leverage Ratio | 2.000 | 1.326 | 1.302 | 1.164 | 1.121 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.815 | -3.083 | -4.586 | -3.786 | -3.959 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | 1.035 | 1.031 | 1.018 | 1.028 | |
| Debt Service Coverage Ratio | -34.061 | -32.230 | -34.261 | -41.348 | -50.040 | |
| Interest Coverage Ratio | -36.112 | -33.147 | -35.251 | -42.567 | -54.649 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2.512 | -2.524 | -2.445 | -2.108 | -2.503 | |
| Capital Expenditure Coverage Ratio | -66.385 | -28.750 | -32.756 | -56.410 | -35.180 | |
| Dividend Paid And Capex Coverage Ratio | -66.385 | -28.750 | -32.756 | -56.410 | -35.180 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.026 | -2.956 | -2.265 | -5.487 | -7.110 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 4.794 | ▼-3.158 | ▼-7.297 |
| Quick Ratio | 4.794 | ▼-3.158 | ▼-7.297 |
| Solvency Ratio | -1.869 | ▼-0.087 | ▲0.064 |
| Cash Ratio | 3.590 | ▲1.808 | ▲0.260 |
| Price To Earnings Ratio | -2.263 | ▲0.913 | ▲1.986 |
| Price To Earnings Growth Ratio | -0.224 | ▼-0.829 | ▼-0.155 |
| Forward Price To Earnings Growth Ratio | -0.224 | ▼-0.829 | ▼-0.155 |
| Price To Earnings Diluted Ratio | -2.263 | ▲0.913 | ▲1.986 |
| Price To Earnings Diluted Growth Ratio | -0.224 | ▼-0.829 | ▼-0.155 |
| Price To Book Ratio | 4.273 | ▲2.384 | ▲1.964 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -2.495 | ▲1.454 | ▲3.008 |
| Price To Operating Cash Flow Ratio | -2.532 | ▲1.553 | ▲3.109 |
| Debt To Assets Ratio | 0.336 | ▲0.198 | ▲0.177 |
| Debt To Equity Ratio | 0.672 | ▲0.488 | ▲0.422 |
| Debt To Capital Ratio | 0.402 | ▲0.247 | ▲0.222 |
| Long Term Debt To Capital Ratio | 0.334 | ▲0.234 | ▲0.216 |
| Financial Leverage Ratio | 2.000 | ▲0.675 | ▲0.618 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.815 | ▼-1.732 | ▼-0.769 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | ▼-0.020 | ▼-0.010 |
| Debt Service Coverage Ratio | -34.061 | ▼-1.831 | ▲4.327 |
| Interest Coverage Ratio | -36.112 | ▼-2.966 | ▲4.233 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -2.512 | ▲0.012 | ▼-0.094 |
| Capital Expenditure Coverage Ratio | -66.385 | ▼-37.635 | ▼-22.489 |
| Dividend Paid And Capex Coverage Ratio | -66.385 | ▼-37.635 | ▼-22.489 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.026 | ▲0.930 | ▲1.943 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $709.9M | $785.5M | $514.6M | $1.03B | $886.6M | |
| Enterprise value | $612.5M | $750.5M | $516.0M | $942.2M | $813.5M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -2.19x | -3.90x | -2.78x | -7.36x | -9.90x | |
| EV / Free cash flow | -2.15x | -3.77x | -2.70x | -7.23x | -9.62x | |
| EV / EBITDA | -2.03x | -2.96x | -2.27x | -5.49x | -7.11x | |
| Net debt / EBITDA | 0.32x | 0.14x | -0.01x | 0.50x | 0.64x | |
| Current ratio | 4.79x | 7.95x | 10.72x | 17.52x | 19.46x | |
| Income quality | 0.89x | 0.78x | 0.86x | 0.73x | 0.70x | |
| Graham net-net | $1 | $4 | $5 | $8 | $7 | |
| Tax burden | 99.8% | 100.2% | 100.2% | 100.2% | 97.4% | |
| Interest burden | 102.9% | 95.0% | 92.5% | 99.9% | 101.9% | |
| Working capital | $220.9M | $433.5M | $393.2M | $558.8M | $383.2M | |
| Invested capital | $269.5M | $486.1M | $445.6M | $611.1M | $438.8M | |
| Return on assets | -94.4% | -44.9% | -44.2% | -27.0% | -25.6% | |
| Operating ROA | -72.4% | -50.4% | -41.4% | -32.0% | -24.2% | |
| Return on tangible assets | -94.4% | -44.9% | -44.2% | -27.0% | -25.6% | |
| Return on equity | -188.9% | -59.5% | -57.6% | -31.4% | -28.7% | |
| Return on invested capital | -114.8% | -53.1% | -52.0% | -28.7% | -26.6% | |
| Return on capital employed | -116.7% | -53.5% | -52.5% | -28.9% | -27.6% | |
| Earnings yield | -44.2% | -31.5% | -41.9% | -17.0% | -13.3% | |
| Free cash flow yield | -40.1% | -25.3% | -37.1% | -12.7% | -9.5% | |
| Capex / Op. cash flow | -1.5% | -3.5% | -3.1% | -1.8% | -2.8% | |
| Capex / Depreciation | 102.9% | 190.9% | 213.3% | 92.8% | 108.8% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 298d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | -298d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-9.6%EV / Sales n/aEV / EBITDA ▲+31.5%EV / Op. cash flow ▲+1.719Earnings yield ▼-0.127
Profitability
Return on equity ▼-1.295Return on assets ▼-0.496Return on invested capital ▼-0.617Return on capital employed ▼-0.632Operating ROA ▼-0.220Income quality ▲+0.116Tax burden ▼-0.004
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-3.158Net debt / EBITDA ▲+0.185Working capital ▼-212627000.000Invested capital ▼-216548000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-19.9%EV / Sales n/aEV / EBITDA ▲+71.5%EV / Op. cash flow ▲+7.714Earnings yield ▼-0.309
Profitability
Return on equity ▼-1.602Return on assets ▼-0.689Return on invested capital ▼-0.882Return on capital employed ▼-0.891Operating ROA ▼-0.482Income quality ▲+0.197Tax burden ▲+0.024
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-297.744Operating cycle n/aCash conversion cycle ▲+297.744Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-14.670Net debt / EBITDA ▼-0.317Working capital ▼-162330000.000Invested capital ▼-169285000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-08-15 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL NEW YORK, Aug. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 2026-08-14 REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
- 2026-08-14 Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit LOS ANGELES, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR REPLIMUNE GROUP, INC.
- 2026-08-14 Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.
- 2026-08-13 INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL The law firm of [url="]Robbins Geller Rudman and Dowd LLP[/url] announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) securities between
- 2026-08-13 INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL SAN DIEGO--(BUSINESS WIRE)---- $REPL #REPL--The case alleges Replimune and certain of its executives made false and/or misleading statements to investors.
- 2026-08-13 REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Replimune Group, Inc. Investors - Contact Kirby McInerney LLP by October 5, 2026 NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
- 2026-08-13 SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL Replimune told investors its RP1 resubmission was a complete response to the FDA''s prior deficiency letter and that commercial launch teams stood ready; the agency''s April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of Replimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class action on behalf of shareholders who purchased between October 20, 2025 and April 10, 2026.
- 2026-08-13 REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky Levi and Korsinsky, LLP reminds purchasers of Replimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class action on behalf of shareholders who p
- 2026-08-13 Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the "Class Period").